DE GREEF RODERICK 4

What Happened Roderick De Greef, President, CEO and a director of BioLife Solutions (BLFS), received three restricted stock awards on Feb 24, 2026 totaling 508,045 shares (118,730 + 170,291 + 219,024). Concurrently, 153,196 shares were withheld to cover tax withholding obligations related to vesting (67,010 and 86,186 shares), at $22.65 per share, generating proceeds of $1,517,777 and $1,952,113 respectively (total $3,469,890). The awards were granted under BioLife’s 2023 Omnibus Performance Incentive Plan as part of 2026 compensation.

Key Details

• Transaction date: Feb 24, 2026; Form 4 filed Feb 26, 2026 (within typical 2-business-day reporting window).
• Awards received (code A): 118,730; 170,291; 219,024 shares — total 508,045 shares granted.
• Tax withholding (code F): 67,010 and 86,186 shares withheld and “disposed” from the reporting person's holdings at $22.65/share, netting $1,517,777 and $1,952,113 (total $3,469,890).
• Shares owned after the transactions: not specified in this filing.
• Footnotes: awards granted under the 2023 Plan. One award vests 25% after one year then quarterly (F1). One award vested at ~156% of the grant based on total shareholder return vs. peers (F2, F3). One award vested at 200% based on specific performance metrics (F4, F5). The withheld-share entries reflect tax withholding tied to those vestings.

Context These transactions are primarily grants of restricted stock that vested (including market- and performance-based vesting multipliers) and routine withholding of shares to satisfy tax obligations. Shares withheld for taxes are not open-market sales to a third party and are generally considered administrative — they do not necessarily indicate the insider is reducing economic exposure.